On The Offense: Sanofi Suits Up For A Game Change
Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.
Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.